OncoLink Cancer Treatment and Resources

Interpreting the TURP Results

Last Modified: October 23, 2005

Question

Dear OncoLink "Ask The Experts,"
After receiving a TURP procedure, I was told that a T1B, 3+3 tumor was found in 19 out of the 99 slices of prostate tissue removed. The tumor's presence was not reflected in an elevated PSA score or a digital exam. What does the (B)3+3 rating mean?

Answer

Richard Whittington, MD, Associate Professor of Radiation Oncology at the University of Pennsylvania School of Medicine, responds:

"(B) 3+3" are actually the two critical parameters in staging and prognosis. This is a T1b, Gleason 6 (3+3) prostate cancer.

T1 means no palpable disease (unable to feel it on digital exam). T1a is incidental cancer with Gleason score <8 and fewer than 5% of the chips in a TURP specimen containing tumor. Stage T1B is defined as a Gleason 8-10 or >5% of the TURP chips containing tumor. Stage T1c is no palpable tumor but a positive biopsy (done because of an elevated PSA). T2 disease means a palpable nodule within the gland on digital rectal exam: T2a if the nodule is less than 1/2 of one lobe, T2b if more than 1/2 of one lobe, and T2c if both lobes.

The Gleason 6 score (see Gleason description below) is a combination of two sub-scores that tells you how big the tumor is and how aggressively it may behave.

The important thing to keep in mind is that the hierarchy of good vs. bad tumors does not directly correlate to the staging system. T1a has the best prognosis, followed by T1c/T2a. T2b is next, followed by T1b, followed by T2c.

Gleason score: The pathologist characterizes how much the cancer looks like normal prostate tissue, and this is known as the grade of the tumor. Pathologists often use a scale when they grade prostate tumors known as the Gleason score. The Gleason score runs from 2 to 10, with 2 being a very normal looking tumor and 10 being a very abnormal looking tumor. Generally, the more abnormal the tumor looks, the more aggressively it acts. We characterize grades on a scale because, together with staging, it gives us a way to offer a prognosis and it often guides our choice of therapy.

OncoLink I wish u knew...

Ms. Wagner discusses diet during cancer treatment and balancing nutritional needs and side effects. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS